Verstovsek S, et al. Results of a prospective, randomized, open-label Phase III study of ruxolitinib in polycythemia vera patients resistant to or intolerant of hydroxyurea: The RESPONSE Trial. Abstract #7026. 50th American Society of Clinical Oncology (ASCO) Chicago, IL.
Vardiman JW, et al. Introduction and overview of the classifi cation of the myeloid neoplasms. Swerdlow SH, et al. eds. WHO Classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC ;2008 : pp18-30.